Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Vor Biopharma Inc.

Get SEC filing alerts via email and in your feed for Vor Biopharma Inc.

VOR

Vor Biopharma Inc.

About Vor Biopharma Inc.

Vor Bio is a clinical-stage biotechnology company developing cell and genome engineering therapies for blood cancers, primarily acute myeloid leukemia (AML). Its core platform involves genetically engineering hematopoietic stem cells to create "shielded" transplants that reduce toxicity and enable targeted treatments like CAR-T and antibody-drug conjugates. The company aims to improve transplant outcomes and develop innovative, potentially curative therapies for blood cancer patients worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Vor Biopharma Inc.

1
1
Vor Biopharma Inc. Vor Biopharma Reports $219.6 Million Net Loss in Q1 2026, Focuses on Telitacicept Trials

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Vor Biopharma Inc. Vor Biopharma Reports $696M Net Loss and Focus on Clinical Trials for Autoimmune Diseases

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Vor Biopharma Inc. Vor Biopharma Reports $812.7 Million Net Loss in Latest Quarter, Plans Restructuring

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Vor Biopharma Inc. Vor Biopharma Reports $1.57 Billion Net Loss in Q2 2025 Amid Restructuring Efforts

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Vor Biopharma Inc. Vor Biopharma Reports $32.5 Million Net Loss in Q1 2025, Announces Strategic Shift

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Vor Biopharma Inc. Vor Biopharma Reports $116.9 Million Net Loss for Fiscal Year 2024, Continues Clinical Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Vor Biopharma Inc. Vor Biopharma Reports Improved Financials, Advances Clinical Programs, and Faces Nasdaq Compliance Challenge

Via official filing (AI summary) | over 1 year ago | 0 comments